 |
| |
|
| |
|
| Nuclear Imaging Procedures |
| Thyroid Consultation & Nuclear Therapy |
| Consultation for the evaluation and treatment of thyroid disorders is available with our consultants who have more than 40 years experience in the field. |
| |
| Radioisotopes are also used for treatment of various types of diseases |
| |
- Hyperthyroidism – 131Iodine (supplied by BARC)
- Differentiated thyroid carcinoma (follicular and papillary) – 131Iodine
- Bone pain palliation – 153Samarium (153Sm-EDTMP) 186Rhenium (186Re-HEDP)
89Strontium (89Sr) – Imported and expensive
32Phosphorous (32P) – supplied by BARC
- Neuroendocrine tumours – 131I-MIBG
(Neuroblastoma, pheochromocytoma)
- Radiation Synovectomy - 90Yttrium, 169Erbium and 186Rhenium
- GEP endocrine tumour – 90Yttrium - Octreotide
|
| |
|
| |
Post therapy whole body iodine scan showing residual thyroid tissue
Normal uptake in stomach, intestines and bladder |
| |
| Radionuclides suitable for systemic metabolic radiotherapy of bone pain include 32Phosphorous (32P), 89Strontium (89Sr), 186Rhenium (186Re) chelated |
| with hydroxyethylidene diphosphonate (HEDP) and 153Samariumm (153Sm) chelated with ethylene diamine tetramethylene phosphonate (EDTMP). Considerable bone marrow suppression due to the presence of higher energy β particles, is the major constraint towards the widespread use of 32P (Mean β =695keV, t1/2=14.3 days) and 89Sr (Mean β =583keV, t1/2=50.5 days). Apart from that, the absence of image-able g photons and long half life (especially in case of 89Sr), are often cited as drawbacks. Beta emitters with short half-lives, like 186Re (Mean β =362keV, γ=137keV, t1/2=3.7 days) and 153Sm (Mean β =233keV, γ=103keV, t1/2=1.9 days), deliver their radiation dose at higher dose rates, which may be therapeutically more effective than equivalent doses given at lower dose rates. The short range of beta emission of these radionuclides may be of advantage in limiting red marrow irradiation. |
| |
| |
| |
|
|
|
|
|
|
